StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Xilio Therapeutics's price to sales ratio was 0.9× on Nov 11, 2026, against 1.2× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.9×−0.2
2025Dec 31, 20251.0×–

More Xilio Therapeutics figures

See a number that looks wrong?